Pediatrics
Conference Coverage
U.S. chikungunya epidemic would likely put rheumatologists on front line
SNOWMASS, COLO. – The continental United States is vulnerable to an epidemic of chikungunya virus disease, an event which would have profound...
From the Journals
Pediatric lupus patients face large burden of serious infection
Children with systemic lupus erythematosus have high rates of serious infections requiring hospitalization, especially those with lupus nephritis...
From the Journals
Methotrexate prolonged efficacy of steroid injections in oligoarticular JIA
The combination of intra-articular corticosteroids and methotrexate could take center stage in treat-to-target strategies for children with...
From the Journals
Opinions vary considerably on withdrawing drugs in clinically inactive JIA
There’s no one way to stop or taper medications for young patients with clinically inactive JIA.
News from the FDA/CDC
Increase brings flu activity back to seasonal high
The level of influenza-like illness activity was highest in five states for the week ending Jan. 21, compared with three states the week before,...
From the Journals
Genetic studies link JIA subtypes to adult diseases, show uniqueness of systemic disease
Two new studies of the genetic relationships between the seven designated categories of juvenile idiopathic arthritis provide compelling support...
Conference Coverage
Prenatal exposure to TNF inhibitors does not increase infections in newborns
WASHINGTON
Conference Coverage
Prenatal exposure to hydroxychloroquine cuts risk of neonatal cutaneous lupus
WASHINGTON - Prenatal hydroxychloroquine reduces the risk of cutaneous neonatal lupus by 60% among the infants of women with a systemic autoimmune...
Conference Coverage
VIDEO: TNF inhibitors don’t boost cancer risk in JIA
WASHINGTON – Tumor necrosis factor inhibitors don't appear to confer any additional cancer risk upon children with juvenile idiopathic arthritis...
Conference Coverage
VIDEO: Biologics: Proposed guideline addresses perioperative management
Biologic agents should be stopped prior to elective total knee or hip arthroplasty in patients with rheumatic diseases, according to a draft...
News from the FDA/CDC
FDA: Etanercept first biologic approved for pediatric psoriasis
Etanercept has been approved for treating children and adolescents, aged 4-17 years, with chronic moderate to severe plaque psoriasis.